Get startedLog in
    Picture of Santhera Pharmaceuticals Holding AG logo

    SANN — Santhera Pharmaceuticals Holding AG News Story

    0.000.00%
    ch flag iconLast trade - 00:00
    HealthcareSpeculativeSmall CapMomentum Trap
    All News

    Brief: Santhera: Agamree Approved In EU For Treatment Of DMD In Patients Aged 4 And Older

    Picture of Santhera Pharmaceuticals Holding AG logoSanthera Pharmaceuticals Holding AG
    18/12/2023 06:02
    Dec 18 (Reuters) - Santhera Pharmaceuticals Holding AG
 SANN.S :
    * AGAMREE® (VAMOROLONE) HAS BEEN APPROVED IN EUROPEAN UNION
(EU)
FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS 4
YEARS OF AGE AND OLDER
    * FIRST COMMERCIAL LAUNCH OF AGAMREE®, IN GERMANY, EXPECTED
IN
Q1-2024

Source text for Eikon:  ID:nGNE64L4RP 
Further company coverage:  SANN.S 

 (Reporting by Berlin Newsroom)
 ((berlin.newsroom@thomsonreuters.com;))

    Recent news on Santhera Pharmaceuticals Holding AG

    See all news